Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ocrelizumab Proves Efficacious in MS Treatment

Ann Pharmacother; ePub 2017 Dec 12; Stahnke, et al

Ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS), demonstrated efficacy in the treatment of relapsing and primary progressive MS (PPMS), according to a recent literature review, and is the first therapy approved for patients with PPMS. A comprehensive literature search was conducted using search terms “ocrelizumab” and “multiple sclerosis” using the date range of 1946 through October 2017. Investigators found:

  • A phase II trial established 600 mg intravenously every 6 months as the preferred dosing schedule.
  • 2 phase III trials evaluated the efficacy of ocrelizumab in patients with relapsing remitting MS, and individual and pooled analysis demonstrated a significant reduction in annualized relapse rate, disability progression at 12 weeks, and gadolinium-enhancing lesions on magnetic resonance imaging (MRI).
  • Patients with PPMS were evaluated in a third phase III trial, which showed a significant decrease in disease progression at 12 weeks and volume of T2-weighted lesions on MRI.
Citation:

Stahnke AM, Holt KM. Ocrelizumab: A new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis. [Published online ahead of print December 12, 2017]. Ann Pharmacother. doi:10.1177/1060028017747635.

This Week's Must Reads

Potential Limitations of Balance Confidence Scales, Int J MS Care; ePub 2018 Jan 24; Wood, Wajda, et al

Cognitive Phenotypes in MS and Targeted Treatments, J Neurology; ePub 2018 Jan 22; Leavitt, Tosto, et al

Demographic Characteristics in Persons with MS, J Int Neuropsychol Soc; 2018 Feb; Costa, et al

Mercy Evaluation of MS Appropriately Valid, Clin Neuropsychol; ePub 2018 Jan 23; Merz, et al

Walking Speed, Endurance Studied in Persons with MS, J Neurophysiol; ePub 2018 Jan 3; Almuklass, et al

Must Reads in Multiple Sclerosis

Potential Limitations of Balance Confidence Scales, Int J MS Care; ePub 2018 Jan 24; Wood, Wajda, et al

Cognitive Phenotypes in MS and Targeted Treatments, J Neurology; ePub 2018 Jan 22; Leavitt, Tosto, et al

Demographic Characteristics in Persons with MS, J Int Neuropsychol Soc; 2018 Feb; Costa, et al

Mercy Evaluation of MS Appropriately Valid, Clin Neuropsychol; ePub 2018 Jan 23; Merz, et al

Walking Speed, Endurance Studied in Persons with MS, J Neurophysiol; ePub 2018 Jan 3; Almuklass, et al